Education
About Us
Working with TipRanks
Follow Us
Zhengye Biotechnology Holding Ltd. (ZYBT)
NASDAQ:ZYBT
ZYBT Stock Chart & Stats
$1.13
--
Market closed
$1.13
--
Day’s Range― - ―
52-Week Range$0.70 - $14.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)871.70K
Market Cap
$36.97M
Enterprise Value$67.83M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.59
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding47,391,376
10 Day Avg. Volume198,467
30 Day Avg. Volume871,704
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageA debt-to-equity of 0.30 and a strong equity ratio indicate balance-sheet flexibility and lower refinancing risk. Over 2-6 months this supports continued R&D and operating investments without urgent capital raises, preserving strategic optionality for partnerships or product development.
Operational ProfitabilityEBIT and EBITDA margins at these levels show structural operational efficiency in manufacturing and services. Sustained margins enable internal funding of programs and cushioning against revenue variability, supporting long-term product development and commercial scale-up.
Diversified Revenue ModelMultiple revenue streams—product sales, licensing, contract research and partnership funding—reduce single-product dependency. This structural diversification improves resilience to clinical or market setbacks and supports steadier funding for R&D and commercialization over months.
Bears Say
Declining RevenueDouble-digit revenue decline and negative multi-period growth highlight a shrinking top line. Persisting contraction reduces scale benefits, pressures long-term investment capacity, and can force reprioritization of development programs or cuts to commercial expansion.
Weak Cash GenerationA steep fall in free cash flow and low operating-cash-to-net-income ratio indicate limited internal liquidity. Over several months this constrains R&D and capex spending, increases reliance on external funding, and raises execution risk for clinical and commercialization milestones.
Margin Compression & Lower ROESignificant gross and net margin erosion alongside lower ROE points to worsening profitability and returns to shareholders. If sustained, this weakens the firm's ability to invest organically and may reduce investor confidence in management's capacity to restore profitable growth.
Zhengye Biotechnology Holding Ltd. News
ZYBT FAQ
What was Zhengye Biotechnology Holding Ltd.’s price range in the past 12 months?
Zhengye Biotechnology Holding Ltd. lowest stock price was $0.70 and its highest was $14.30 in the past 12 months.
What is Zhengye Biotechnology Holding Ltd.’s market cap?
Zhengye Biotechnology Holding Ltd.’s market cap is $36.97M.
When is Zhengye Biotechnology Holding Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhengye Biotechnology Holding Ltd.’s earnings last quarter?
Currently, no data Available
Is Zhengye Biotechnology Holding Ltd. overvalued?
According to Wall Street analysts Zhengye Biotechnology Holding Ltd.’s price is currently Overvalued.
Does Zhengye Biotechnology Holding Ltd. pay dividends?
Zhengye Biotechnology Holding Ltd. does not currently pay dividends.
What is Zhengye Biotechnology Holding Ltd.’s EPS estimate?
Zhengye Biotechnology Holding Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhengye Biotechnology Holding Ltd. have?
Zhengye Biotechnology Holding Ltd. has 47,391,376 shares outstanding.
What happened to Zhengye Biotechnology Holding Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhengye Biotechnology Holding Ltd.?
Currently, no hedge funds are holding shares in ZYBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhengye Biotechnology Holding Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
4.06%
Trailing 12-Months
Asset Growth
-4.13%
Trailing 12-Months
Company Description
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. It offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. The company also exports its products to Vietnam, Pakistan, and Egypt. The company was founded in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Technical Analysis
China Pharma Holdings
―
China SXT Pharmaceuticals
―
Qilian International Holding Group Limited
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.13% Other Institutional Investors
99.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---